产品
编 号：F622542
分子式：C19H17BClN3O3
分子量：381.62
分子式：C19H17BClN3O3
分子量：381.62
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1620899-32-2
产品详情
生物活性：
AN7973 is the 6-carboxamide benzoxaborole, blocks intracellular parasite development and inhibits Cryptosporidium growth. AN7973 is orally active, possesses favorable safety, stability, and PK parameters, and is an exciting agent candidate for treating cryptosporidiosis.
体内研究：
AN7973 (oral gavage; 5-25 mg/kg; once daily) is efficacious in murine models of both acute and chronic infection by rapidly eliminating C.parvum in vivo.AN7973 (oral gavage; 5 mg/kg, 10 mg/kg, 6.67 mg/kg; once daily, twice daily, three times daily) reduces C.parvum fecal shedding, diarrhea, and dehydration in a neonatal calf model (closely mimics that seen in infants) of cryptosporidiosis.AN7973 possesses favorable safety, stability, and PK parameters as an exciting drug candidate for treating cryptosporidiosis.Animal Model:Four to five weeks NOD scid gamma mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)(NSG) with chronic Cryptosporidium infection
Dosage:10 mg/kg, 20 mg/kg
Administration:Oral gavage; 10 mg/kg, 20 mg/kg; once daily
Result:Reduced parasite shedding by >99% at a dose of 25?mg/kg and by >90% at a dose of 10?mg/kg administration.
Animal Model:Four-week-old female C57BL/6 IFN-γ?/? mice with acute Cryptosporidium infection
Dosage:5 mg/kg, 10 mg/kg, 25 mg/kg
Administration:Oral gavage; 5 mg/kg, 10 mg/kg, 25 mg/kg; once dairy
Result:Eliminated C.parvums at a dose-dependent efficacy.
Animal Model:One-day-old to two-day-old Holstein bull Neonatal calf model of cryptosporidiosis
Dosage:5 mg/kg, 10 mg/kg, 6.67 mg/kg
Administration:Oral gavage; 5 mg/kg, 10 mg/kg, 6.67 mg/kg; once daily, twice daily, three times daily
Result:Curtailed parasite shedding and completely eliminated diarrhea.
AN7973 is the 6-carboxamide benzoxaborole, blocks intracellular parasite development and inhibits Cryptosporidium growth. AN7973 is orally active, possesses favorable safety, stability, and PK parameters, and is an exciting agent candidate for treating cryptosporidiosis.
体内研究：
AN7973 (oral gavage; 5-25 mg/kg; once daily) is efficacious in murine models of both acute and chronic infection by rapidly eliminating C.parvum in vivo.AN7973 (oral gavage; 5 mg/kg, 10 mg/kg, 6.67 mg/kg; once daily, twice daily, three times daily) reduces C.parvum fecal shedding, diarrhea, and dehydration in a neonatal calf model (closely mimics that seen in infants) of cryptosporidiosis.AN7973 possesses favorable safety, stability, and PK parameters as an exciting drug candidate for treating cryptosporidiosis.Animal Model:Four to five weeks NOD scid gamma mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)(NSG) with chronic Cryptosporidium infection
Dosage:10 mg/kg, 20 mg/kg
Administration:Oral gavage; 10 mg/kg, 20 mg/kg; once daily
Result:Reduced parasite shedding by >99% at a dose of 25?mg/kg and by >90% at a dose of 10?mg/kg administration.
Animal Model:Four-week-old female C57BL/6 IFN-γ?/? mice with acute Cryptosporidium infection
Dosage:5 mg/kg, 10 mg/kg, 25 mg/kg
Administration:Oral gavage; 5 mg/kg, 10 mg/kg, 25 mg/kg; once dairy
Result:Eliminated C.parvums at a dose-dependent efficacy.
Animal Model:One-day-old to two-day-old Holstein bull Neonatal calf model of cryptosporidiosis
Dosage:5 mg/kg, 10 mg/kg, 6.67 mg/kg
Administration:Oral gavage; 5 mg/kg, 10 mg/kg, 6.67 mg/kg; once daily, twice daily, three times daily
Result:Curtailed parasite shedding and completely eliminated diarrhea.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备